Compare Repligen Corporation Common Stock (RGEN) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Synopsys, Inc. — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Synopsys, Inc. trades at $477.56 (market cap $94.77B). The key difference: Synopsys, Inc. is far larger — about 8.5× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Synopsys, Inc. for 72 Days on average.
| RGEN | SNPS | |
|---|---|---|
Market Cap | $11.14B | $94.77B |
Volume | 1,259,263 | 2,520,237 |
Sector | Health | Technology |
52-Week High | $194.57 | $534.56 |
52-Week Low | $102.87 | $367.70 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $11.02B | $102.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Synopsys (SNPS) trades at $479.93, down 4.49% today but remains in a strong technical uptrend with bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $3.91 beating expectations by 6.5% and maintains strong profitability with 72.38% gross margins. Recent investor day announcements highlighted transformative AI partnerships with OpenAI and Amazon, driving positive sentiment and analyst upgrades.
Outlook remains positive with 93% analyst buy ratings and $575.93 consensus target offering 20% upside. Key opportunities include AI-driven chip design growth and Ansys integration synergies, while risks involve execution challenges and premium valuation at 86.3 P/E. The stock presents a compelling growth story but requires monitoring of integration progress and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
